In addition, high levels of HMGR mRNA in breast cancer patients is associated with poor clinical outcome, suggesting a potential strategy that could be used in conjunction with BMF-mediated personalized therapy (Fiorillo et al. Here, HMGA1 is linked to breast carcinoma.